Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics-Reference-Cited by-同舟云学术

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

Published:2019-07-25 Issue:11 Volume:46 Page:2298-2310
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Seban Romain-David,Nemer John S.,Marabelle Aurélien,Yeh Randy,Deutsch Eric,Ammari Samy,Moya-Plana Antoine,Mokrane Fatima-Zohra,Gartrell Robyn D.,Finkel Grace,Barker Luke,Bigorgne Amélie E.,Schwartz Lawrence H.,Saenger Yvonne,Robert Caroline,Dercle Laurent^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-019-04411-7.pdf

Reference48 articles.

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

2. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.

3. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–9.

4. Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018;29:2115–20.

5. Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, et al. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/−L1 therapy. Eur J Cancer. 2016;65:33–42.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons;Cancers;2024-05-24

2. Fluorine-18 fluorodeoxyglucose uptake change in liver, mediastinal blood pool, and lymphoid cell–rich organs during programmed cell death-1 immunotherapy in lymphoma;Nuclear Medicine Communications;2024-05-10

3. Theranostics-enabling high-tech centers: the value of centralizing resources in countries in development;F1000Research;2024-04-17

4. PET/Computed Tomography Transformation of Oncology;PET Clinics;2024-04

5. The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management;Advanced Pharmaceutical Bulletin;2024-03-10